Merus (NASDAQ:MRUS) Given Average Recommendation of "Buy" by Brokerages

Merus (NASDAQ:MRUS - Get Free Report) has been given an average rating of "Buy" by the sixteen ratings firms that are presently covering the firm, Marketbeat reports. Fourteen analysts have rated the stock with a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among analysts that have updated their coverage on the stock in the last year is $85.31.

A number of brokerages recently weighed in on MRUS. Guggenheim reissued a "buy" rating and issued a $109.00 price objective on shares of Merus in a research note on Friday, March 28th. HC Wainwright restated a "buy" rating and issued a $85.00 price objective on shares of Merus in a research note on Monday, March 3rd. Wells Fargo & Company assumed coverage on shares of Merus in a report on Friday, February 7th. They set an "overweight" rating and a $91.00 price objective for the company. William Blair reissued an "outperform" rating on shares of Merus in a research report on Friday, February 28th. Finally, Piper Sandler assumed coverage on shares of Merus in a report on Thursday, February 13th. They set an "overweight" rating and a $84.00 price target for the company.

Institutional Trading of Merus

Several large investors have recently made changes to their positions in the business. GAMMA Investing LLC lifted its holdings in Merus by 2,153.6% during the 1st quarter. GAMMA Investing LLC now owns 631 shares of the biotechnology company's stock worth $27,000 after buying an additional 603 shares in the last quarter. State of Wyoming bought a new stake in Merus during the 4th quarter worth about $48,000. Wells Fargo & Company MN lifted its holdings in Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company's stock valued at $59,000 after buying an additional 300 shares during the period. GF Fund Management CO. LTD. acquired a new stake in Merus during the 4th quarter worth $60,000. Finally, Avior Wealth Management LLC bought a new stake in shares of Merus during the 4th quarter valued at $76,000. Institutional investors own 96.14% of the company's stock.

Remove Ads

Merus Stock Up 8.7 %

Shares of MRUS traded up $3.35 during mid-day trading on Monday, hitting $41.97. 832,258 shares of the company's stock were exchanged, compared to its average volume of 712,988. The stock has a market cap of $2.90 billion, a price-to-earnings ratio of -10.63 and a beta of 1.02. The firm has a fifty day moving average of $43.65 and a two-hundred day moving average of $45.25. Merus has a twelve month low of $33.19 and a twelve month high of $61.61.

Merus (NASDAQ:MRUS - Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($0.89) by $0.48. Merus had a negative net margin of 680.61% and a negative return on equity of 38.89%. The firm had revenue of $9.14 million for the quarter, compared to the consensus estimate of $10.57 million. On average, equities analysts predict that Merus will post -3.85 earnings per share for the current year.

About Merus

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.